foto london banner.jpg

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Medius Deal Watch June 2018

June has proved to be a very busy month on the deal front with significant ...

Read More

Avacta looks to deals to leverage Affimer platform...

Key learnings: UK-based Avacta Group has developed Affimer® technology, an ...

Read More

Building a thriving life sciences hub in the Nordi...

On Thursday 30 August, an expert panel will take to the stage at the inaugu...

Read More

Investorview: Why people are key in life science i...

Since it was founded in 1996, European venture capital firm HealthCap has i...

Read More

Investorview: Plugging knowledge gaps to accelerat...

Venture capital firm Hadean Ventures closed its first fund at the end of 20...

Read More

Xplico: Supporting strategic decision-making throu...

Key learnings: Headquartered in Copenhagen, Xplico has been providing valua...

Read More

Novoheart expands global presence to support comme...

Key learnings: Novoheart has developed human bioengineered heart constructs...

Read More

PhoreMost raises £11m Series A round to progress t...

Key learnings: PhoreMost completed its Series A round in May 2018, with a t...

Read More

Medius Deal Watch May 2018

This month’s top deals are noticeably in the category of acquisitions rathe...

Read More

Five misconceptions about whistleblowing systems p...

Would you like to be able to identify risk - whether it be reputational, fi...

Read More

Aparito applies remote patient monitoring tech to ...

Key learnings: Wales-based digital health company Aparito utilises wearable...

Read More

Cognetivity’s AI-driven cognitive test seeks to ad...

Key learnings: Cognetivity Neurosciences was named joint winner in the Inno...

Read More

Add Your Response